Seeking Alpha

Cerium Pharmaceuticals Synacthen, a treatment for infantile spasms, is no threat to Questcor's...

Cerium Pharmaceuticals Synacthen, a treatment for infantile spasms, is no threat to Questcor's (QCOR -7.3%) Acthar for a number of reasons, says PropThink's David Moskowitz. First, the drug is known to contain benzyl alcohol which has been implicated in infant toxicity, and FDA approval for a product containing this ingredient in infants is highly unlikely. Second, QCOR's Acthar Gel already has Orphan Drug status with an exclusivity for infantile spasms that doesn't expire until 2017. Lastly, infantile spasms represent only a small fraction of Acthar sales, so it would have minimal impact.
Comments (1)
  • TruffelPig
    , contributor
    Comments (4059) | Send Message
     
    Better late then never. SA should have not published the initial wrong statement without fact check.
    2 Nov 2012, 09:17 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|